M&T Bank Corp Decreases Holdings in Abbott Laboratories $ABT

Key Points

• M&T Bank cut its Abbott stake by 91.5% in Q4, selling 777,875 shares and leaving 72,405 shares worth about $9.07 million.
• Analysts have trimmed price targets recently, but the stock retains a consensus rating of "Moderate Buy" with an average price target of $119.43.
• Abbott slightly beat quarterly EPS and revenue, set FY2026 EPS guidance of 5.38–5.58, and pays a $0.63 quarterly dividend (about a 2.8% yield).

M&T Bank Corp decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 91.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,405 shares of the healthcare product maker's stock after selling 777,875 shares during the quarter. M&T Bank Corp's holdings in Abbott Laboratories were worth $9,072,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Danica Pension Livsforsikringsaktieselskab purchased a new stake in Abbott Laboratories in the 3rd quarter valued at approximately $185,640,000. Asset Management One Co. Ltd. lifted its stake in Abbott Laboratories by 2.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker's stock valued at $115,032,000 after buying an additional 19,966 shares in the last quarter. Nordea Investment Management AB lifted its stake in Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker's stock valued at $43,785,000 after buying an additional 18,974 shares in the last quarter. AE Wealth Management LLC lifted its stake in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker's stock valued at $8,774,000 after buying an additional 11,264 shares in the last quarter. Finally, Mawer Investment Management Ltd. lifted its stake in Abbott Laboratories by 5.9% in the 3rd quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker's stock valued at $168,199,000 after buying an additional 70,122 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Argus reduced their target price on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday. UBS Group reduced their target price on Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Barclays reduced their target price on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research note on Monday, April 20th. BTIG Research reiterated a "buy" rating and issued a $131.00 price target on shares of Abbott Laboratories in a report on Friday, April 17th. Finally, Benchmark cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $119.43.

Abbott Laboratories Trading Down 1.4%

Shares of ABT opened at $91.16 on Friday. The stock has a fifty day moving average of $105.96 and a two-hundred day moving average of $117.34. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a market capitalization of $158.76 billion, a PE ratio of 25.53, a price-to-earnings-growth ratio of 1.54 and a beta of 0.79. Abbott Laboratories has a fifty-two week low of $90.72 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.Abbott Laboratories's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio is presently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president owned 146,377 shares of the company's stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.